Second, given that DEPTOR is considered to be a potential therapeutic target in some cancers, such as multiple myeloma 33, our study also suggest that targeting DEPTOR to repress its expression through a variety of means, such as disturbing its transcription or promoting its degradation 5, 14-17, 28, 34, 35, and especially by developing proteolysis-targeting chimeric molecules that directly degrade DEPTOR 36, might have potential therapeutic value in ErbB2-overexpressing breast cancer. The gene discussed is DEPTOR; the disease is plasma cell myeloma.